Bridgefront Capital, LLC Neurocrine Biosciences Inc Transaction History
Bridgefront Capital, LLC
- $249 Million
- Q3 2024
A detailed history of Bridgefront Capital, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bridgefront Capital, LLC holds 4,662 shares of NBIX stock, worth $553,892. This represents 0.22% of its overall portfolio holdings.
Number of Shares
4,662Holding current value
$553,892% of portfolio
0.22%Shares
6 transactions
Others Institutions Holding NBIX
# of Institutions
643Shares Held
94.3MCall Options Held
634KPut Options Held
603K-
Black Rock Inc. New York, NY14.2MShares$1.69 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.2 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$612 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$306 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$221 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.4B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...